The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.
Vivex Biologics chairman John McCallum breaks down the challenges, costs, and strategies behind bringing medical innovations ...
Some U.S. health regulators who review medical devices and tobacco products for safety and efficacy are struggling to meet ...
Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...
Orthocell receives US FDA 510(k) approval for Remplir, its flagship nerve repair product and can now start commercial ...
WA biotech Orthocell has received US Food and Drug Administration clearance for its flagship nerve repair product.
In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its ...